Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D7K3FB
|
|||
| Drug Name |
CPX-POM
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Bladder cancer [ICD-11: 2C94; ICD-9: 188] | Phase 2 | [1] | |
| Solid tumour/cancer [ICD-11: 2A00-2F9Z] | Phase 1 | [2] | ||
| Company |
CicloMed
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Ribonucleotide reductase (RIR) | Target Info | Inhibitor | [3] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT04525131) Safety, Dose Tolerance, Pharmacokinetics, Pharmacodynamics of CPX-POM in Patients With Newly Diagnosed or Recurrent Bladder Tumors. U.S. National Institutes of Health. | |||
| REF 2 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 3 | Preclinical Pharmacokinetics of Fosciclopirox, a Novel Treatment of Urothelial Cancers, in Rats and Dogs. J Pharmacol Exp Ther. 2019 Aug;370(2):148-159. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.